Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Picks and shovels in solar sector


Bookmark and Share

 "I’ve always been partial to going with the 'pick-and-shovel' companies; in the solar sector, that means buying the companies that make the equipment that makes photovoltaic (PV) panels," says Gregg Early.

In The New World, the high tech expert offers a pair of plays: Spire Corp. (NASDAQ: SPIR) and CVD Equipment (NYSE: CVV).

"The companies I like have established positions in markets that have a proven commitment to distributed power generation and continue to make major investments in renewable energy technologies, with solar being the lead technology.

"Two pick-and-shovel companies that I like are tiny companies, but they’ve been working smart, expanding their customer base and gaining strong international reputations along the way.

Advertisement
Banner

"Spire is a Massachusetts based company that is closely held--about 80% of its stock is held by the CEO and executive officers--and has come into its own as a manufacturer of turnkey PV production lines.

"Much of its recent business is selling facilities to power companies in Europe and Asia that are interested in making their own PV systems as opposed to contracting to large foreign PV firms. The advantage of these deals is it allows these companies to stay in control of the knowledge base.

"Although its business may suffer along with the sector, most of this has been priced in already, or, as Warren Buffett said of the market in general, overpriced in. Spire Corp is a buy at current levels if you have some risk capital you want to play with.

"CVD is another company that’s a worthy speculation if you’re interested in getting to the pick and shovel makers of the US PV industry. 

"CVD is an acronym that stands for chemical vapor deposition, which is a chemical process for building high-performance, high-purity solid materials by converting gases into solids and layering them on substrates.

"CVD doesn’t make equipment for university and Fortune 500 research labs, but it has a uniquely skilled workforce that will partner with small companies to help develop technologies that pass scrutiny.

"For the startup, that means more money can go into materials and research than going about the expensive and time intensive process of staffing skilled scientists.

"In these times especially, this strategic partnering is a very attractive possibility to start-ups and R&D facilities of big companies as well.

"CVD also has been very involved in flexing its nanotech muscles, which has certainly boosted its PV business, in particular thin film PV.

"Its First Nano product group manufactures the EasyTube equipment product line used by researchers around the world to develop and grow a wide variety of next generation nanowire, nanotube and thin film materials.

"And the big kicker is, the company doubled its revenues in 2008. It’s even hard for me to believe they pulled that one off in such a lousy economy, but this is what’s so compelling about this little company. And management is solid and committed. CVD Equipment is a buy at these levels."


Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary